Encorafenib plus binimetinib combined BRAF-MEK inhibitors

Melanoma

All type of patients:  1 trials  - COLUMBUS

encorafenib plus binimetinib vs vemurafenib

No demonstrated result

suggested progression or death (progression free survival PFS) by 46% (not demonstrated)




- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons